SecBot SecBot
8-K ·Filed Jun 30, 2026

PCRX

Pacira BioSciences, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001628280-26-046136
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The $70M upfront cash infusion and debt paydown significantly strengthen Pacira's balance sheet, removing a potential overhang. The revenue milestones provide upside optionality through 2031. Watch for Q3 2026 close and subsequent 10-Q for debt reduction details and updated guidance reflecting the streamlined biopharma focus. The spasticity program collaboration adds an incremental catalyst path.

DirectionBullish
Confidencehigh
Horizonweeks

EXPAREL

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially marketed since 2011.
Next catalyst
None dated

What to watchEXPAREL is a mature, approved product with no upcoming binary drug catalyst. The stock trades at the $36.50 Viatris acquisition price, so the near-term move depends entirely on deal closing (expected by end of 2026). Watch for the Ninth Circuit royalty ruling's impact on EXPAREL margins and any updates on the tender offer's regulatory clearance.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.37
T+0 close · Jun 30, 2026 · via day close
Latest settled
−2.92%
T+60 · $24.63
Vs SPY
−6.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $25.37entry
  2. T+1 · 5mo ago −1.34%α −1.20% · $25.03
  3. T+5 · 4mo ago +0.87%α +0.26% · $25.59
  4. T+20 · 4mo ago +4.34%α +5.36% · $26.47
  5. T+60 · 8w ago −2.92%α −6.48% · $24.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M in total consideration ($70M upfront cash plus up to $70M in future revenue-based milestones). The deal includes collaboration on a spasticity program. Proceeds will be used to repay Pacira's senior secured revolving credit facility, strengthening its balance sheet. This divestiture advances Pacira's transition into a pure biopharmaceutical company focused on non-opioid therapies.

Key Financial Metrics

Deal Value
$140.0M
Deal Type
acquisition

Key Facts

  • Pacira to receive $70M upfront cash for the iovera divestiture to Zimmer Biomet
  • Total potential consideration up to $140M including $70M in revenue-based milestone payments through 2031
  • Upfront proceeds to be used to pay down Pacira's senior secured revolving credit facility
  • 66 employees (~8% of workforce) expected to transfer to Zimmer Biomet at closing
  • Transaction expected to close in Q3 2026, subject to customary conditions
  • Pacira and Zimmer Biomet will collaborate on advancing the spasticity program, with potential incremental compensation for Pacira upon successful study and regulatory approval

Financial Impact

Up to $140M total consideration ($70M upfront) for iovera divestiture, with upfront cash used to reduce debt

revenuedebt

Risk Factors

  • Revenue milestones of up to $70M are contingent on iovera commercial performance and may not be achieved
  • Transaction requires customary closing conditions and may be delayed or terminated
  • Execution risk in transitioning 66 employees and related operations to Zimmer Biomet
  • Removal of iovera revenue stream could pressure near-term reported revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-046136
Exhibit: exhibit991-ioverapressrele.htm0001628280-26-046136
Document: 0001628280-26-046136-index-headers.html0001628280-26-046136
Document: 0001628280-26-046136-index.html0001628280-26-046136
Document: 0001628280-26-046136.txt0001628280-26-046136

Track record

29 reports on PCRX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026